Long-Acting HIV Treatment and Prevention Are Coming: From Laboratory to Marketplace

The FDA will have to determine that these new products are safe and effective, but the complexity of issues related to long-acting products creates substantial obstacles to efficient FDA review.

Read report here.

In partnership with amfAR, the O’Neill Institute published a series of issue briefs. The briefs provide examination of critical policy issues that impact access, availability and acceptability of PrEP and long-acting agents, which are innovative forms of PrEP and HIV treatments that are under development and do not require daily pill taking. The series of briefs highlight the education and policy dialogues needed to prepare for innovative long-acting products transmission and reduce health care spending.

Read all four reports in this series here.